A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of Duvakitug in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

This is a parallel, Phase 2b, 3-arm, double-blind, randomized, multicenter, multinational, placebo-controlled, dose-ranging study to evaluate the efficacy and the safety of different doses of duvakitug in adult participants with moderate to severe hidradenitis suppurativa.
Study details include:
* The study duration will be up to 145 weeks , including a 4-week screening period, a 16-week initial double-blind treatment period, a 24-week active blinded extension period, a 96-week long-term extension period and a 5-week follow-up period.
* The treatment duration will be up to 40 weeks for the participants who will stop after the active blinded extension period and up to 136 weeks for the participants who will continue in the long-term extension period.
* The number of visits will be up to 23 for the participants who will stop after the active blinded extension period and up to 71 for the participants who will continue in the long-term extension period.

开始日期2026-10-13

申办/合作机构

Sanofi

CTIS2025-524617-84-00

/ Completed临床1期

A study to investigate the pharmacokinetics and safety of a single dose of duvakitug in healthy adult participants

开始日期2026-04-09

申办/合作机构

Sanofi-Aventis Recherche & Développement SA

NCT07184944

/ Recruiting临床3期

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Phase 3, Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include:
The study duration may be up to 286 weeks including:
* 40-week Pivotal Maintenance Sub-Study
* 240-week Open-Label Extension (OLE) Sub-Study
* 45-day Follow-Up visit
Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit.
The treatment duration may be up to 280 weeks including:
* 40 weeks in the Pivotal Maintenance Sub-Study
* 240 weeks in OLE Sub-Study
The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study

开始日期2026-01-22

申办/合作机构

Sanofi

[+1]

100 项与 Duvakitug 相关的临床结果

登录后查看更多信息

100 项与 Duvakitug 相关的转化医学

登录后查看更多信息

100 项与 Duvakitug 相关的专利（医药）

登录后查看更多信息

项与 Duvakitug 相关的文献（医药）

2026-10-01·Nature Reviews Gastroenterology & Hepatology

Relieving IBD with duvakitug

Article

作者: Ray, Katrina

2026-09-01·The Lancet Gastroenterology & Hepatology

Efficacy and safety of duvakitug in patients with ulcerative colitis (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Article

作者: Reinisch, Walter ; Barkay, Hadas ; Abrams, Ken ; Singh, Rajendra ; Stepek, David ; Sands, Bruce E ; Danese, Silvio ; Levine, Phillip ; Kempinski, Radoslaw ; Gross, Nicholas ; Jairath, Vipul ; Ratiu-Duma, Bogdan

BACKGROUND:

Ulcerative colitis is a chronic inflammatory disease affecting the colon and rectum. We aimed to investigate the efficacy and safety of duvakitug, an anti-TNF-like cytokine 1A (TL1A) monoclonal antibody, in adults with moderately to severely active ulcerative colitis.

METHODS:

In this multicentre, placebo-controlled, phase 2b study, we randomly assigned (1:1:1) adults aged 18-75 years with moderately to severely active ulcerative colitis (including patients with inadequate response, loss of response, or intolerance to previous conventional or advanced therapies) to receive a 2250 mg loading dose of duvakitug (subcutaneously), followed by either 450 mg or 900 mg doses every 2 weeks, or placebo loading dose followed by placebo every 2 weeks. The primary endpoint was clinical remission (modified Mayo score) at week 14, analysed using Bayesian methodology. A duvakitug dose was declared successful if the posterior probability that the response rate exceeded placebo was 0·90 or greater. Analyses were done in the modified intention-to-treat population, which included all patients who received at least one dose of their assigned treatment. This trial was registered with ClinicalTrials.gov, NCT05499130, and has been completed.

FINDINGS:

Patients were enrolled between Sept 30, 2022 and Nov 12, 2024. We screened 260 patients with ulcerative colitis. Of these, we randomly assigned 137 (53%) patients to receive duvakitug (n=47 450 mg and n=46 900 mg) or placebo (n=44; modified intention-to-treat analysis set). Patients had a mean age of 41·0 years (SD 13·1); 86 (63%) were men, 51 (37%) were women, and 132 (96%) were White. 43 (31%) patients had previous exposure to an approved advanced therapy. 17 (36%) of 47 patients in the duvakitug 450 mg group and 22 (48%) of 46 patients in the duvakitug 900 mg group were in clinical remission at week 14, compared with nine (20%) of 44 patients in the placebo group. Differences in posterior mean response rates versus placebo were 15% (95% credible interval [CrI] -3 to 33) for duvakitug 450 mg and 26% (95% CrI 8 to 44) for duvakitug 900 mg, with posterior probabilities of superiority to placebo exceeding the prespecified threshold for declaring efficacy (0·95 in the 450 mg group and >0·99 in the 900 mg group). Adverse event incidence was similar with duvakitug (23 [49%] of 47 patients in the 450 mg group and 20 [43%] of 46 in the 900 mg group) and placebo (23 [52%] of 44). The most frequently occurring adverse events were anaemia (one in the 450 mg group, one in the 900 mg group, and three in the placebo group) and upper respiratory tract infection (three in the 450 mg group, one in the 900 mg group, and one in the placebo group). One serious adverse event occurred in the 900 mg group (non-infective oophoritis) and one in the placebo group (intracranial haemorrhage).

INTERPRETATION:

Duvakitug showed significant evidence for clinical remission versus placebo, with no safety concerns identified, in patients with moderately to severely active ulcerative colitis.

FUNDING:

Teva and Sanofi.

2026-09-01·The Lancet Gastroenterology & Hepatology

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

Article

作者: Duvall, George Aaron ; Barkay, Hadas ; Abrams, Ken ; Singh, Rajendra ; Jairath, Vipul ; Sands, Bruce E ; Danese, Silvio ; Reinisch, Walter ; Levine, Phillip ; Kierkuś, Jaroslaw ; Gross, Nicholas ; Ratiu-Duma, Bogdan

BACKGROUND:

Crohn's disease is a chronic, relapsing inflammatory disease of the gastrointestinal tract. We aimed to assess the efficacy and safety of duvakitug, an anti-TNF-like cytokine 1A monoclonal antibody, in adults with moderately to severely active Crohn's disease.

METHODS:

In this multicentre, placebo-controlled, phase 2b study, we enrolled adults (aged 18-75 years) with moderately to severely active Crohn's disease (including inadequate response, loss of response, or intolerance to previous therapies). We randomly assigned (1:1:1) participants to receive 2250 mg duvakitug loading dose subcutaneously, followed by duvakitug 450 mg or 900 mg every 2 weeks, or placebo loading dose, then placebo every 2 weeks. The primary endpoint, endoscopic response (≥50% reduction from baseline in Simple Endoscopic Score for Crohn's Disease) at week 14, was analysed using Bayesian methodology. A duvakitug dose was declared successful if the posterior probability that the response rate exceeded placebo was at least 0·90. Analyses were done in the modified intention-to-treat population, which included all patients who received at least one dose of their assigned treatment. This trial was registered with ClinicalTrials.gov, NCT05499130, and has been completed.

FINDINGS:

Patients were enrolled from Sept 30, 2022, to Nov 12, 2024. We screened 275 patients with Crohn's disease, of whom 139 (51%) patients were randomly assigned to receive either duvakitug 450 mg (n=46), duvakitug 900 mg (n=47), or placebo (n=46). One patient in the duvakitug 900 mg did not receive study drug; the modified intention-to-treat population therefore included 46 patients in the 450 mg group, 46 in the 900 mg group, and 46 in the placebo group. 78 (57%) patients were previously exposed to at least one advanced therapy. The mean age of enrolled patients was 39·5 years (SD 14·7); 58 (42%) were female, 80 (58%) were male, and 131 (95%) were White. 12 (26%) of 46 patients in the duvakitug 450 mg group, 22 (48%) of 46 in the duvakitug 900 mg group, and six (13%) of 46 in the placebo group had an endoscopic response at week 14. The difference in posterior mean response rates versus placebo was 13% (95% credible interval -3 to 29) for duvakitug 450 mg and 33% (16 to 50) for duvakitug 900 mg, with posterior probabilities of superiority of 0·94 for duvakitug 450 mg and greater than 0·99 for duvakitug 900 mg. Adverse events occurred in 31 (67%) of 46 patients in the duvakitug 450 mg group, 20 (43%) of 46 in the duvakitug 900 mg group, and 22 (48%) of 46 in the placebo group. The most frequent adverse events were nasopharyngitis (two in the 450 mg group, three in the 900 mg group, and three in the placebo group) and headache (four in the 450 mg group, one in the 900 mg group, and one in the placebo group). Serious adverse events occurred in six (13%) patients in the duvakitug 450 mg group, one (2%) in the duvakitug 900 mg group, and five (11%) in the placebo group.

INTERPRETATION:

Duvakitug showed significant evidence for endoscopic response versus placebo in patients with moderately to severely active Crohn's disease, with no safety concerns identified.

FUNDING:

Teva and Sanofi.

242

项与 Duvakitug 相关的新闻（医药）

2026-09-28

·IBDer的小圈子

新药TL1A抑制剂，和五种老药比怎么样？——溃疡性结肠炎、克罗恩病患者读懂版

如果你或家人正在治疗溃疡性结肠炎或克罗恩病，可能听过乌司奴、古塞奇尤、利生奇珠、乌帕替尼、英夫利西。现在又出现一个陌生名字：TL1A抑制剂。你可以把它想成一种“新路线的消炎针”：它不去直接堵TNF或IL-23，而是去关掉TL1A这个信号，而这个信号既和炎症有关，也可能和肠道变硬、变窄（纤维化）有关。不过，TL1A抑制剂目前公开的数据主要来自早期（II期）研究，人数有限，也没有和上面五种药做过直接“擂台赛”。所以下面的对比，不是要评出谁第一，而是帮你看懂：它们思路哪里不同、数据大概怎样、有什么希望和不确定。读完后，你更能和医生聊清楚：哪种方案更适合你现在的病情。目前能否用、是否获批，以医生和药监信息为准。基于现有TL1A抑制剂（主要为duvakitug和tulisokibart）的II期临床数据，与乌司奴单抗、古塞奇尤单抗、利生奇珠单抗、乌帕替尼及英夫利西单抗进行全方位文本对比，目前尚无任何直接头对头（head-to-head）比较研究，以下分析均基于跨试验的间接描述，需审慎解读。作用机制的定位差异 TL1A抑制剂靶向的是TNF样配体1A（TL1A）与其受体DR3构成的信号轴。该通路的核心特点在于同时驱动免疫激活与纤维化重塑——TL1A不仅能作为T细胞共刺激因子放大Th1/Th17炎症反应，还能直接刺激成纤维细胞、破坏上皮屏障，并激活固有淋巴样细胞（ILC3）产生GM-CSF。这一机制定位使其与现有五款药物形成鲜明差异：英夫利西单抗（抗TNF）和乌司奴单抗（抗IL-12/23 p40）均聚焦于细胞因子中和，古塞奇尤单抗与利生奇珠单抗（抗IL-23 p19）选择性阻断Th17轴，乌帕替尼（JAK1抑制剂）则通过胞内激酶抑制多条细胞因子信号。TL1A抑制剂独特的抗纤维化潜力是目前其他四类机制均不具备的差异化特征。临床疗效的间接对比溃疡性结肠炎（UC）诱导期：duvakitug在RELIEVE UCCD II期试验中，14周临床缓解率（改良Mayo评分）为36%（450 mg）和48%（900 mg），安慰剂为20%。tulisokibart在ARTEMIS-UC试验中12周临床缓解率为26%，安慰剂仅1.5%。作为参照，乌司奴单抗在UC诱导期（UNIFI试验）第8周临床缓解率约为19%，生物制剂经治人群约26%；古塞奇尤单抗静脉诱导第12周临床缓解率为23%。TL1A抑制剂在诱导期的绝对缓解率数值上似乎更高，但各试验人群的既往治疗暴露程度不同，tulisokibart试验中约72%患者为抗TNF经治，而duvakitug试验的具体基线特征需进一步核实。克罗恩病（CD）：duvakitug在CD队列中14周内镜下应答率为26%（450 mg）和48%（900 mg），安慰剂13%。利生奇珠单抗在AFFIRM III期试验中皮下诱导的CDAI临床缓解率为55%，安慰剂30%；真实世界中利生奇珠单抗第12周临床缓解率约49.7%。乌司奴单抗在CD中的诱导缓解率（TNFi经治人群）约10–17%。TL1A抑制剂在CD内镜终点上的表现值得关注，但其数据来自II期小样本，与III期数据不可直接对比。维持期：duvakitug 44周维持数据显示，UC临床缓解率在900 mg组达58%、450 mg组47%；CD内镜应答率分别为55%和41%。乌司奴单抗UNIFI维持44周临床缓解率约24–29%；古塞奇尤单抗QUASAR长期扩展研究中第92周临床缓解率高达71–74%（非应答者插补分析）；乌帕替尼在真实世界UC维持期（12–16周）临床缓解率约71%。维持期数据因试验设计、分析人群和终点定义差异极大，难以横向比较。安全性与免疫原性的维度 TL1A抑制剂的II期安全性特征总体可控。duvakitug维持期最常见不良事件（≥5%）包括上呼吸道感染、鼻咽炎、克罗恩病和高血压，与诱导期一致。tulisokibart的不良事件率与安慰剂相当。免疫原性方面，TL1A抑制剂面临一个独特挑战：其抗药物抗体（ADA）可能与其他TL1A抗体甚至组合药物（如古塞奇尤单抗）发生交叉结合，因部分第三方抗TL1A抗体之间存在序列同源性。相比之下，英夫利西单抗的ADA发生率最高可达83%，阿达木单抗最高54%，而乌司奴单抗、维多珠单抗和戈利木单抗的ADA率仅为1–19%。TL1A抑制剂的ADA数据尚不成熟，长期免疫原性风险有待III期试验验证。给药方式与患者便利性英夫利西单抗需静脉输注，乌司奴单抗和古塞奇尤单抗具备静脉诱导+皮下维持的双路径，利生奇珠单抗已获批皮下诱导，乌帕替尼为每日口服。duvakitug采用每4周一次皮下注射的维持方案，且其Fc工程化改造（Xtend技术）旨在延长半衰期以减少注射频率。如果这一半衰期优势在III期中得到验证，TL1A抑制剂在给药便利性上有望介于口服JAK抑制剂与现有生物制剂之间。综合定位 TL1A抑制剂代表了一类机制全新的IBD治疗选项，其抗纤维化和TNF非依赖性抗炎特性是现有药物均不具备的。从现有II期数据看，其在诱导期的缓解率数值不逊于甚至可能优于IL-23和IL-12/23抑制剂，但这一印象受II期小样本和人群异质性影响，不能作为疗效优越性的依据。与乌帕替尼和英夫利西单抗相比，TL1A抑制剂的起效速度和绝对缓解率尚需III期验证。当前最合理的定位是：为抗TNF和IL-23经治失败的患者提供一种机制互补的新选择，而非替代现有任一药物。总的来说，TL1A抑制剂代表一个新方向，不是现有药物的简单复制。它可能给抗TNF或IL-23效果不理想、或担心肠道纤维化的患者多一个选择，维持期每4周皮下注射也可能更方便。但它还不是“神药”：目前没有和乌司奴、古塞奇尤、利生奇珠、乌帕替尼、英夫利西直接比较，早期数据不能说明它一定更强，长期安全性和疗效还要等更大规模研究。选药像配钥匙，没有最好，只有更适合。请把这份对比拿给主治医生，结合病情、既往用药、感染风险、医保和生育计划一起决定，不要自行换药或停药。治疗选择越来越多，本身就是好消息。

临床2期申请上市临床终止临床结果临床申请

2026-09-27

·新药笔记

赛诺菲34亿元买来的肠炎新药第5次报进中国！TL1A抗体duvakitug正做全球III期，默沙东同靶点药刚被拟纳入突破性治疗

CDE官网显示，9月24日，赛诺菲的Duvakitug注射液一项临床试验申请获得受理，受理号JXSL2600260，进口1类新药。这是一款靶向TL1A的全人源单抗，治疗溃疡性结肠炎和克罗恩病这两种最常见的炎症性肠病（IBD），2023年赛诺菲付给梯瓦（Teva）5亿美元首付（按9月24日人民币汇率中间价约合34亿元），拿下共同开发和商业化权益，研发费用两家对半分。来源：CDE官网这不是它第一次进中国。按药品名称在CDE临床试验默示许可页查询，duvakitug此前已拿到4个临床许可（JXSL2500202至205），溃疡性结肠炎、克罗恩病各两个。这次新受理的申请，受理页不显示适应症，要等拿到默示许可后才能看到。来源：CDE官网 II期：一年随访，疗效没掉下来 TL1A是一种会放大肠道炎症、推动肠壁纤维化的信号分子，堵住它，理论上既能消炎，也可能减少肠道变窄、梗阻这类纤维化并发症。 duvakitug的II期RELIEVE UCCD在溃疡性结肠炎和克罗恩病患者里同时做。2024年12月，赛诺菲公布14周诱导期结果：溃疡性结肠炎患者中，低、高剂量组分别有36.2%、47.8%达到临床缓解，安慰剂组20.45%；克罗恩病患者中，低、高剂量组分别有26.1%、47.8%达到内镜应答，安慰剂组13.0%。赛诺菲当时说，这是第一个在克罗恩病中做随机、安慰剂对照的TL1A抗体研究。今年2月公布的维持期数据更关键：诱导期起效的130名患者继续用药44周，溃疡性结肠炎患者900 mg、450 mg组分别有58%、47%处于临床缓解，克罗恩病患者分别有55%、41%达到内镜应答。常见不良事件是上呼吸道感染、鼻咽炎等。来源：赛诺菲官网 III期已开跑，中国在里面按ClinicalTrials.gov登记，duvakitug的4项III期（溃疡性结肠炎、克罗恩病各一项诱导研究和一项维持研究）2025年9月同时登记，目前都在招募。其中溃疡性结肠炎诱导研究、克罗恩病的诱导和维持研究，研究中心所在国家都包括中国。另一个新动向：9月10日，赛诺菲在ClinicalTrials.gov登记了duvakitug治疗中重度化脓性汗腺炎的IIb期研究，计划入组156人，预计10月启动。这是它第一次走出肠病。梯瓦在2月的新闻稿里说过，今年会宣布更多适应症。同一靶点，三家大药企都押了重注 TL1A是近三年炎症领域最贵的靶点之一。2023年，默沙东花108亿美元（约729亿元）收购Prometheus拿到tulisokibart（MK-7240）；罗氏花71亿美元首付（约479亿元）收购Telavant拿到afimkibart；赛诺菲则是和梯瓦共同开发、平摊研发费用。2024年，艾伯维也花1.5亿美元首付和近期里程碑，从中国公司FutureGen引进了临床前TL1A抗体FG-M701。三家大药企的TL1A抗体在中国都已经动起来了：来源：CDE官网按药品名称查询（受理页、默示许可页、突破性治疗公示），2026-09-27；交易金额据Fierce Biotech 默沙东在中国铺得最广。它的MK-7240在中国已拿到10个临床许可，9月16日，CDE拟将其用于中度至重度化脓性汗腺炎的申请纳入突破性治疗，并标注为罕见病药物，公示期到9月22日结束。9月22日当天，默沙东又一项MK-7240临床申请获受理。来源：CDE官网值得注意的是，默沙东和赛诺菲的TL1A抗体几乎同时转向了化脓性汗腺炎。这是一种反复发作、在腋下和腹股沟长脓肿、会留下窦道和疤痕的慢性皮肤炎症，现有生物药选择不多。默沙东在中国已进入突破性治疗程序，赛诺菲的IIb期刚在海外登记。赛诺菲9月24日这个新的中国临床申请是不是化脓性汗腺炎，目前CDE没有公开适应症，只能等默示许可公布。三家大药企的TL1A抗体已经在中国排进同一张时间表，赛诺菲靠II期一年数据追赶，默沙东靠适应症铺得广；接下来看赛诺菲这次新申请的适应症，以及谁先在国内拿下化脓性汗腺炎。 Copyright © 2026 新药笔记. All Rights Reserved. 免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，本号不对任何主体因使用本文内容而导致的任何损失承担责任。

临床2期临床3期并购突破性疗法申请上市

2026-09-23

·小红书

溃疡性结肠炎，TL1A新药研发爆发

💊Duvakitug是一款人源IgG1-入2单抗，靶向TL1A。TL1A中文全称为肿瘤坏死因子（TNF）-样配体1A，在近年来受到行业广泛青睐。研究发现，TL1A在自身免疫性疾病中异常表达。从作用机制上来看，TL1A通过其DR3受体在肠道炎症级联和纤维化中起关键作用。因此，针对TL1A靶点的药物有望用于治疗溃疡性结肠炎、克罗恩病等多种自身免疫性疾病。 💊2025年2月，赛诺菲与梯瓦公布了duvakitug在2b期临床研究RELIEVE UCCD中获得的详细结果。结果显示，接受duvakitug治疗的溃疡性结肠炎（UC）和克罗恩病（CD）患者在第14周时达成缓解。 💊目前正在全球开展3期临床研究，国内50家研究中心参与，计划纳入98例中度至重度UC参与。 #药物科普 #溃疡性结肠炎 #溃结 #UC #溃结 #炎症性肠病 #美

100 项与 Duvakitug 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12950	-	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
溃疡性结肠炎	临床3期	美国	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	中国	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	日本	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	保加利亚	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	加拿大	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	捷克	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	法国	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	德国	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	匈牙利	Sanofi	2025-10-08
溃疡性结肠炎	临床3期	立陶宛	Sanofi	2025-10-08

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05499130 (RELIEVE UCCD, Pubmed \| Lancet Gastroenterol Hepatol)	临床2期	克罗恩病	139	Duvakitug 450 mg	壓窪鏇獵繭獵鑰襯窪膚(齋鹹鏇鹹範衊願鏇醖壓) = 蓋窪鹹壓簾鑰齋範積網蓋獵糧糧簾廠膚艱鏇願 (遞繭顧醖選鏇積遞糧鑰 ) 更多	积极	2026-09-01
				Duvakitug 900 mg	壓窪鏇獵繭獵鑰襯窪膚(齋鹹鏇鹹範衊願鏇醖壓) = 襯積鹽壓窪遞獵淵遞製蓋獵糧糧簾廠膚艱鏇願 (遞繭顧醖選鏇積遞糧鑰 ) 更多
NCT05499130 (RELIEVE UCCD, Pubmed \| Lancet Gastroenterol Hepatol)	临床2期	溃疡性结肠炎	137	Duvakitug 450 mg	觸積艱齋襯顧壓繭鑰選(築膚選構餘繭簾窪築襯) = 顧繭範淵願艱製醖窪鑰築餘鏇淵積觸繭遞獵繭 (鑰窪壓觸壓鬱願齋積鏇 ) 更多	积极	2026-09-01
				Duvakitug 900 mg	觸積艱齋襯顧壓繭鑰選(築膚選構餘繭簾窪築襯) = 選窪鬱醖艱選範衊選醖築餘鏇淵積觸繭遞獵繭 (鑰窪壓觸壓鬱願齋積鏇 ) 更多
NCT05499130 (RELIEVE UCCD, CTgov)	临床2期	克罗恩病 \| 溃疡性结肠炎	290	placebo+TEV-48574 (Placebo (UC))	積製積願餘憲齋繭積糧 = 壓願壓糧淵齋齋艱鏇積遞鹹觸鹹網醖衊餘壓積 (鏇窪壓鏇衊衊餘醖願築, 醖餘鏇艱膚淵糧鏇積醖 ~ 選製糧衊鑰觸夢觸簾糧) 更多	-	2025-12-05
				TEV-48574 (TEV-48574 450 mg (UC))	積製積願餘憲齋繭積糧 = 簾餘積網醖選願製艱選遞鹹觸鹹網醖衊餘壓積 (鏇窪壓鏇衊衊餘醖願築, 鹹窪壓網鹹築夢衊簾廠 ~ 齋選膚獵鬱構構製餘廠) 更多
NCT05499130 (RELIEVE UCCD, NEWS \| Company_Website 1 \| Company_Website 2) 人工标引	临床2期	克罗恩病 \| 溃疡性结肠炎	240	duvakitug (UC + 450 mg)	窪繭憲齋膚簾簾壓鬱廠(鑰廠壓願選顧鹽齋鬱鬱) = 選鬱襯艱膚醖鑰襯鹹艱醖願夢選艱遞鏇觸夢糧 (餘蓋廠顧遞選鑰壓襯積 ) 达到更多	积极	2024-12-17
				duvakitug (UC + 900 mg)	窪繭憲齋膚簾簾壓鬱廠(鑰廠壓願選顧鹽齋鬱鬱) = 衊簾觸顧選衊衊觸衊願醖願夢選艱遞鏇觸夢糧 (餘蓋廠顧遞選鑰壓襯積 ) 达到更多
NCT04545385 (CTgov)	临床2期	哮喘	65	Placebo (Placebo)	餘夢鹽襯憲窪齋顧夢積 = 繭顧蓋糧鬱壓糧鹽齋艱簾窪鬱積窪繭鏇獵壓簾 (襯遞餘構餘範選積餘願, 網簾窪鹽淵製構淵獵簾 ~ 襯糧窪齋構顧製鑰淵構) 更多	-	2023-03-13
				TEV-48574 (TEV-48574)	餘夢鹽襯憲窪齋顧夢積 = 糧積網窪憲獵艱製觸積簾窪鬱積窪繭鏇獵壓簾 (襯遞餘構餘範選積餘願, 餘繭觸鏇鏇製醖壓夢遞 ~ 餘壓願構醖齋遞簾衊蓋) 更多